LEXICON PHARMACEUTICALS Q2 FY26 earnings call LXRX

Lexicon completed enrollment for its Phase III SONATA-HCM study evaluating sotagliflozin in hypertrophic cardiomyopathy (HCM). The study, which is the largest Phase III study to date in both obstructive and nonobstructive HCM, was significantly over-enrolled. Top-line data is anticipated in Q1 2027. The trial design includes a substantial majority of nonobstructive HCM patients and a meaningful cohort of obstructive HCM patients, with the primary efficacy endpoint being improvement in symptoms as measured by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ CSS) at week 26.

Progress continues towards the resubmission of the New Drug Application (NDA) for Zynquista in type 1 diabetes, now expected in Q4 2026. The STENO1 study is on track to achieve the FDA's required patient exposure levels by the end of August, and observed DKA rates are similar to standard of care and below those seen in previous trials. The slight delay from the prior timeline is attributed to the administrative aspects of patient-level data collection and transfer from the investigator-initiated STENO1 study.

LX9851, a first-in-class ACSL5 inhibitor for obesity, is currently in Phase I development under a licensing agreement with Novo Nordisk. Lexicon has already received two $10 million milestone payments from Novo Nordisk and has the potential to receive a third $10 million milestone payment later this year, reflecting continued collaboration and progress on this promising compound.

Lexicon is conducting preclinical studies for pilavapadin, exploring its utility in other potentially high-value indications. The company expresses growing belief in the agent's potential and its novel AAK1 inhibition mechanism of action, with data from these preclinical studies expected to be shared as early as later this year.

The company strengthened its balance sheet, reporting $190.6 million in cash, cash equivalents, and short-term investments as of June 30, 2026, an increase from $125.2 million at the end of 2025. This was aided by a new $100 million debt facility with Hercules Capital, with an initial $55 million tranche funded to repay previous debt. Lexicon reiterated its full-year 2026 operating expense guidance of $100 million to $110 million, including targeted investments in precommercial activities.

Sotagliflozin's unique dual SGLT1 and SGLT2 inhibition directly addresses the underlying diastolic dysfunction characteristic of HCM. By inhibiting SGLT1, SOTA improves cardiac cell function through mechanisms like enhanced calcium flux and reduced inflammatory markers, while SGLT2 inhibition positively affects cardiorenal dysfunction. This dual action positions SOTA as an agent that works both inside and outside the heart, offering a novel and complementary treatment option for HCM patients, potentially as a first-line therapy or in combination with other agents.